Dr. Butler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney Street
Dana Farber Cancer Institute
Boston, MA 02115Phone+1 617-632-2334Fax+1 617-632-3479
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 2000
Johns Hopkins UniversityResidency, Internal Medicine, 1992 - 1995
Yale School of MedicineClass of 1992
Certifications & Licensure
MA State Medical License 1995 - 2012
Clinical Trials
- Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma Start of enrollment: 2007 Aug 01
- Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Start of enrollment: 2016 Sep 01
Roles: Contact, Principal Investigator
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. Start of enrollment: 2022 May 02
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 748 citationsBiologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsF. Stephen Hodi, Martin C. Mihm, Robert J. Soiffer, Frank G. Haluska, Marcus O. Butler
Proceedings of the National Academy of Sciences of the United States of America. 2003-04-15 - 488 citationsImmunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsF. Stephen Hodi, Marcus O. Butler, Darryl A. Oble, Michael V. Seiden, Frank G. Haluska
Proceedings of the National Academy of Sciences of the United States of America. 2008-02-26 - 85 citationsPhase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2Linh T. Nguyen, Samuel Saibil, Valentin Sotov, Michael X. Le, Leila Khoja
Cancer Immunology, Immunotherapy. 2019-02-11
Press Mentions
Accuracy of Skin Cancer Diagnosis Varies by Physician, Exam MethodNovember 14th, 2024- Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal MelanomaJune 8th, 2022
- Asthma Society’s Pollen Tacker Predicts High Pollen Levels This WeekendJuly 14th, 2020
- Join now to see all
Grant Support
- Detection Of Immunogenic Ovarian Cancer AntigensNational Cancer Institute2000–2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
